bmiMD Review: $99 for a single month, the same price at every dose, and a 4.9 from 1,200 Google reviews
bmiMD has the cheapest GLP-1 pricing we have been able to verify anywhere — $99 for a single month of compounded semaglutide with no commitment of any kind, or $96.50/month if you choose to prepay a year, with no separate membership fee and the provider visit included. Two things make that price more interesting than a headline number: it is the same at every dose, so it does not climb as you titrate, and bmiMD is one of the few programs here that publishes the actual potency and sterility specifications its pharmacies test against. It has no FDA warning letter and no FTC action on record — though one lawsuit, a Novo Nordisk trademark suit common to this category, is pending, and we cover it below.
- $99 buys one month, and you do not have to prepay a year to get it. We opened the page our link goes to and read it ourselves: $99 for a single month of compounded semaglutide, no membership fee stacked on top, the provider visit included, free shipping. Prepay a year and it drops to $96.50. Nothing else in this roundup gets close on price, at either end.
- The same price at every dose. This quietly matters more than the headline. Dose-based escalation is how a $99 plan becomes a $300 plan by month four at other providers. Here your month-one number is your month-twelve number.
- It publishes what it tests for. Potency within ±10%, USP 797 sterility, pH, and USP 85 endotoxin testing. Most compounded programs say “quality-tested” and leave it there; bmiMD names the specifications, which is the kind of disclosure you can actually hold a company to.
- A clean record with regulators — but not a lawsuit-free one. We found no FDA warning letter, no FTC action and no state attorney general action naming bmiMD or MEDCCM. There is one lawsuit: Novo Nordisk sued MEDCCM d/b/a bmiMD in May 2025 for trademark infringement, part of a wave of more than a dozen near-identical suits Novo has filed against compounded-semaglutide sellers. The case is in settlement talks. Details below.
- Customers rate it highly where most of them actually review it. bmiMD’s Google profile averages 4.9 out of 5 across roughly 1,200 reviews — the largest third-party review sample the company has anywhere, half again the size of its Trustpilot one.
- Financing built in, and honest labelling. Klarna, Afterpay, FSA and HSA are all accepted, and bmiMD states plainly on its own site that compounded medications are not FDA-approved — a disclosure the regulator has had to force out of other companies.
- Worth knowing: the $96.50 rate is the only one that requires money up front ($1,158 for the year), bmiMD replies to only about one negative Trustpilot review in ten, and its terms and conditions page currently returns a 404. Read the two sections below before you prepay anything.
Pricing — verified on bmiMD’s own site
Unlike the other two programs on this site, bmiMD’s pricing is actually legible. There is no membership fee stacked on top of the medication, the provider visit is included, and shipping is free. One month costs $99 with nothing locked in. Prepaying buys a further discount, and the twelve-month term is the only one that beats the single month.
| Term | Compounded semaglutide | Paid up front |
|---|---|---|
| 1 month | $99 | $99 |
| 3 months | $109/mo | $327 |
| 6 months | $104/mo | $624 |
| 12 months | $96.50/mo | $1,158 |
bmiMD states the price is the same at every dose, which removes the most common hidden-escalation problem in this category. FSA/HSA cards, Klarna and Afterpay are accepted — bmiMD is the only program on this site that puts buy-now-pay-later financing in front of you at checkout, which for a $1,158 twelve-month commitment is a meaningful piece of plumbing.
The quality specifications bmiMD actually publishes
This is the most underrated thing about bmiMD and the reason it outranks two better-known brands in our roundup. Almost every compounded GLP-1 program tells you its medication is “quality-tested” and stops there. bmiMD names the tests: potency within ±10% of label, USP <797> sterility, pH, and USP <85> bacterial endotoxin testing on the compounded product.
Those are the standard release specifications a sterile compounding pharmacy should be meeting, so bmiMD is not claiming anything exotic. The point is that it commits to them in writing, in public, where you can ask about them — and it pairs that with a plain statement on its own site that compounded medications are not FDA-approved. In a category where the FDA has spent a year sending letters about companies blurring exactly that line, a provider that volunteers the limitation is telling you something about how it operates.
The ratings: 4.9 on Google from about 1,200 reviews
bmiMD trades as MEDCCM, Inc., a New York corporation registered on 31 December 2022, at 420 Lexington Avenue, Room 1402, New York, NY 10170.
Start with where most bmiMD customers actually leave their reviews, because the two platforms are not close in size: roughly 1,200 people have rated bmiMD on Google against about 800 on Trustpilot. On Google — still the larger sample — bmiMD averages 4.9 out of 5 as of July 2026. The company embeds these Google reviews directly on its own homepage, and the ones we read are what you would expect at that average: people who got their medication on time, at the price they were quoted, and lost weight.
Trustpilot is the smaller sample — and it is climbing there too. In March 2026 the country mirrors read roughly 3.5 to 3.7 from about 600 reviews; as of late July the listing reads 4.4 out of 5 (“Excellent”) with the count past 800. The distribution is still barbell-shaped and bmiMD still replies to only about 10–11% of negative reviews — but both platforms now point the same direction.
How to read the gap: on the larger sample, the Google 4.9 is the better summary of what usually happens when you order from bmiMD. The Trustpilot barbell tells you what the unhappy minority runs into — mostly refund friction and slow support — and that when they do, the company mostly does not reply. Both things are true at once.
The biggest sample likes it the most
Google: 4.9 from ~1,200 reviews. Trustpilot: 4.4 from 800+ and climbing. The platform where the most customers actually speak is the one that likes bmiMD the most — that ratio is the single most useful ratings fact on this page.
Roughly one negative Trustpilot review in ten gets a reply
Found answers 92% of its critics and TrimRx about 72%. bmiMD answers about 10%. If something goes wrong, expect to do the chasing yourself.
You pay before you are seen
Payment is taken before the clinical consultation. If you are found ineligible you are refunded in full — but the sequence means your card is charged first.
What you get, and what simply is not there
Included
- Compounded semaglutide and compounded tirzepatide, dispensed by 503A pharmacies, availability varying by state.
- The provider visit, at no separate charge.
- Free shipping, and the same price at every dose.
- A wider ancillary menu than the others: sermorelin, NAD+, glutathione, metformin, MIC+B12 and naltrexone/bupropion/B6.
Not available
- Any branded product. No Wegovy, no Zepbound, no Ozempic, no Mounjaro. Compounded only.
- Insurance billing. None, anywhere on the site.
- Lab work. Not included.
- Human coaching. Not offered.
- A mobile app. bmiMD does not have one.
Eligibility is 18 or older with a BMI of 27 or above. bmiMD’s homepage claims availability in all 50 states, but its own March 2026 press release refers only to “states where bmiMD operates.” We treat the all-50 claim as unverified marketing until the company reconciles the two.
Cancellation and refunds
A full refund is available only if you are found ineligible. Once the pharmacy processes your order there are no refunds. Between clinician approval and pharmacy processing there is a $50 cancellation fee.
A compliance flag worth understanding before you buy
Since September 2025 the FDA has issued three waves of letters to telehealth marketers of compounded GLP-1s: roughly 80 letters plus about 40 untitled letters in September 2025, 30 announced on 3 March 2026, and 25 more in June 2026. The recipient list for the March wave was never published.
The conduct those letters cite is consistent: describing a compounded product as a “generic”, implying FDA approval, drawing equivalence between a compounded product and the branded drug, invoking facility-registration status as though it were a quality endorsement, and branding the drug with the telehealth firm’s own name to obscure where it was made.
The Novo Nordisk lawsuit, plainly stated
In May 2025, Novo Nordisk — the maker of Ozempic and Wegovy — sued MEDCCM, Inc. d/b/a bmiMD in the Eastern District of New York (case 2:25-cv-02846) for trademark infringement. Context matters here: this is one of more than a dozen near-identical suits Novo filed against compounded-semaglutide telehealth sellers in 2025, alleging misuse of the Ozempic and Wegovy names in marketing — it is a category-wide enforcement campaign, not a claim about medication safety or patient harm. As of our last check the case was in court-ordered mediation and settlement talks, with no judgment against the company. We flag it because we tell you everything we find, and because an earlier version of this page said bmiMD had no lawsuit on record — that was wrong, and we corrected it.
For context on the direction of travel: the semaglutide and tirzepatide shortages were declared resolved in December 2024 and February 2025, and the compounding grace period ended in May 2025. On 30 April 2026 the FDA proposed excluding semaglutide, tirzepatide and liraglutide from the 503B Bulks List on the grounds of “no clinical need”; the comment period closed on 29 June 2026 and a final determination is pending. That proposal applies to 503B outsourcing facilities and all three programs on this site use 503A pharmacies — but nobody buying a twelve-month prepaid compounded plan today should assume the category looks the same in twelve months.
Check bmiMD’s current price →Who bmiMD is right for
Consider it if
- Price is the deciding factor. At $99 for a single month — or $96.50 a month if you prepay a year — this is the floor of the entire category, and we read both figures off the page our link opens rather than taking anyone’s word for it.
- You want one flat monthly number with no membership fee and no dose-based escalation — the same price in month twelve as in month one.
- You want a provider that publishes its potency and sterility specifications instead of saying “quality-tested” and moving on.
- You weight a 4.9 Google average from ~1,200 customers — the larger of its two review samples — and you are comfortable prepaying on that basis.
- You want ancillary products like NAD+ or sermorelin from the same provider.
Avoid it if
- You want branded Wegovy or Zepbound, or any insurance involvement.
- You want to be able to read the terms you are agreeing to — the T&C page does not load.
- You expect a reply if something goes wrong; roughly one negative review in ten gets one.
- You are not comfortable paying before the clinical consultation happens.
- You want labs, coaching or an app.
Frequently asked questions
How much does bmiMD cost?
Compounded semaglutide is $99 for a single month with no commitment, $109/month on a 3-month term ($327 up front), $104/month on 6 months ($624) and $96.50/month on 12 months ($1,158). There is no separate membership fee, the provider visit is included and shipping is free. bmiMD does not publish what the single-month plan renews at after the first month, so confirm that with support if you take it.
Is bmiMD legitimate?
Yes. bmiMD is the trading name of MEDCCM, Inc., a New York corporation registered in December 2022. We found no FDA warning letter, no FTC action and no state attorney general action naming the company. One lawsuit is pending: Novo Nordisk sued MEDCCM d/b/a bmiMD in May 2025 for trademark infringement, part of a wave of similar suits against compounded-semaglutide sellers; it is in settlement talks. Its Google Business Profile averages 4.9 out of 5 across roughly 1,200 reviews — its largest third-party review sample and larger than its Trustpilot one, where the average sits at 4.4 from more than 800 reviews.
How does bmiMD test its compounded medication?
bmiMD publishes the specifications its compounded product is tested against: potency within plus or minus 10% of label, USP <797> sterility, pH, and USP <85> bacterial endotoxin testing. Naming the specifications rather than saying "quality-tested" is unusually specific for this category. Compounded medications are still not FDA-approved, which bmiMD states plainly on its own site.
Does bmiMD take insurance?
No. There is no insurance billing anywhere on the site. FSA and HSA cards, Klarna and Afterpay are accepted.
Does bmiMD prescribe branded Ozempic or Wegovy?
No. bmiMD dispenses compounded semaglutide and compounded tirzepatide only, through 503A pharmacies. Compounded medications are not FDA-approved.
What is bmiMD's cancellation policy?
A full refund is available only if you are found ineligible. There is a $50 cancellation fee after clinician approval but before the pharmacy processes the order, and no refund once the pharmacy has processed it. These terms come from a company press release; bmiMD's own terms and conditions page returns a 404.
Is bmiMD available in all 50 states?
bmiMD's homepage says yes, but its own March 2026 press release refers only to "states where bmiMD operates." We treat the all-50 claim as unverified until the company reconciles the two statements.
Sources
- bmimd.com — homepage, semaglutide and tirzepatide product pages, pricing verified on-site 27 July 2026.
- bmimd.com — published compounded-product testing specifications (potency ±10%, USP <797> sterility, pH, USP <85> endotoxin) and compounded-medication disclosure.
- bmiMD Google Business Profile (4.9 average from roughly 1,200 reviews as of July 2026; reviews also embedded on bmimd.com’s homepage).
- Trustpilot country mirrors for bmimd.com, March 2026 reading (AU 3.7/617, CA 3.6/607, NZ 3.5/608); the listing read 4.4 from more than 800 reviews when re-checked in late July 2026.
- New York State corporate registration for MEDCCM, Inc.
- Novo Nordisk A/S et al v. MEDCCM, Inc. d/b/a bmiMD, E.D.N.Y. case 2:25-cv-02846, filed 21 May 2025 (trademark infringement; in mediation/settlement proceedings at last check).
- bmiMD press release, March 2026 (cancellation terms and state availability).
- Awin affiliate programme listing for bmiMD (company-supplied member and rating claims).
- FDA warning letters to compounded GLP-1 telehealth marketers, September 2025, 3 March 2026 and June 2026.
- FDA proposal to exclude semaglutide, tirzepatide and liraglutide from the 503B Bulks List, 30 April 2026; comment period closed 29 June 2026.
Figures on this page were checked on 4 August 2026. Prices, promotions and third-party ratings change frequently — always confirm the current price on the provider’s own checkout before you pay.
Go to bmiMD →